Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
grade C 33.1 -1.25% -0.42
MYGN closed down 1.25 percent on Friday, March 22, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical MYGN trend table...

Date Alert Name Type % Chg
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 180 Bullish Setup Bullish Swing Setup -1.25%
Mar 21 Overbought Stochastic Strength -1.25%
Mar 20 New Uptrend Bullish 0.18%
Mar 20 Overbought Stochastic Strength 0.18%
Mar 19 Stochastic Sell Signal Bearish -0.87%
Mar 19 Overbought Stochastic Strength -0.87%
Mar 18 180 Bullish Setup Bullish Swing Setup -2.39%
Mar 18 Overbought Stochastic Strength -2.39%
Mar 15 Narrow Range Bar Range Contraction -1.63%

Older signals for MYGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Ovarian Cancer Medical Genetics Diagnostic Tests Pancreatic Cancer Biomarkers Chemical Pathology Personalized Medicine
Is MYGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 50.44
52 Week Low 26.05
Average Volume 941,352
200-Day Moving Average 37.2588
50-Day Moving Average 30.1984
20-Day Moving Average 31.535
10-Day Moving Average 32.912
Average True Range 1.0735
ADX 24.28
+DI 30.9662
-DI 20.9655
Chandelier Exit (Long, 3 ATRs ) 31.1095
Chandelier Exit (Short, 3 ATRs ) 31.2205
Upper Bollinger Band 35.0485
Lower Bollinger Band 28.0215
Percent B (%b) 0.72
BandWidth 22.283177
MACD Line 0.928
MACD Signal Line 0.737
MACD Histogram 0.191
Fundamentals Value
Market Cap 2.27 Billion
Num Shares 68.6 Million
EPS 0.32
Price-to-Earnings (P/E) Ratio 103.44
Price-to-Sales 3.01
Price-to-Book 2.98
PEG Ratio 3.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.05
Resistance 3 (R3) 34.10 33.84 33.89
Resistance 2 (R2) 33.84 33.60 33.81 33.84
Resistance 1 (R1) 33.47 33.45 33.34 33.42 33.78
Pivot Point 33.21 33.21 33.14 33.18 33.21
Support 1 (S1) 32.84 32.97 32.71 32.78 32.42
Support 2 (S2) 32.58 32.82 32.55 32.36
Support 3 (S3) 32.21 32.58 32.31
Support 4 (S4) 32.15